-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Benzinga·08/03/2026 16:00:55
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.